Avastin Hearing: Genentech, CDER Dispute Relevance Of Second-Line Breast Cancer Data

The parties disagree on whether breast cancer studies conducted outside the first-line setting are relevant to CDER's proposed withdrawal of Avastin's accelerated approval for first-line use.